3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Boasting A 54% Return On Equity, Is Eli Lilly and Company (NYSE:LLY) A Top Quality Stock?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Why Eli Lilly Stock Is Soaring-and How It Plans to Stay on Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson (NYSE: JNJ) back in May of 2023 and hasn’t looked back since.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Pharmaceutical Technology2h
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use AI and tech to transform the company.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
FiercePharma2d
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
FierceBiotech21h
Eli Lilly expands innovation reach with another global Gateway Lab, this time in China
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...